9,658 results match your criteria Parkinson Disease Dementia


Cholinesterase inhibitors and memantine for Parkinson's disease dementia and Lewy body dementia: A meta-analysis.

Exp Ther Med 2019 Mar 24;17(3):1611-1624. Epub 2018 Dec 24.

Department of Neurology, Hebei General Hospital, Shijiazhuang, Hebei 050051, P.R. China.

Recently, several randomized controlled trials on the use of cholinesterase inhibitors or memantine as treatments for cognitive impairment in Parkinson's disease (CIND-PD), Parkinson's disease with dementia (PDD) and dementia with Lewy bodies (DLB) were completed. The present study provided a meta-analysis of these studies to evaluate the efficacy of cholinesterase inhibitors and memantine on CIND-PD, PDD and DLB. The Cochrane Library, Pubmed, Embase and Web of Science databases were searched to retrieve eligible studies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/etm.2018.7129DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6364145PMC

Long-term outcomes of deep brain stimulation in Parkinson disease.

Nat Rev Neurol 2019 Feb 18. Epub 2019 Feb 18.

Department of Clinical and Movement Neurosciences, University College London, Queen Square Institute of Neurology, London, UK.

The efficacy of deep brain stimulation (DBS) for Parkinson disease (PD) is well established for up to 1 or 2 years, but long-term outcome data are still limited. In this Review, we critically discuss the evidence on the long-term outcomes of DBS and consider the clinical implications. Although many patients are lost to follow-up, the evidence indicates that subthalamic nucleus DBS improves motor function for up to 10 years, although the magnitude of improvement tends to decline over time. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41582-019-0145-9DOI Listing
February 2019

Comparative sensitivity of the MoCA and Mattis Dementia Rating Scale-2 in Parkinson's disease.

Mov Disord 2019 Feb 10;34(2):285-291. Epub 2018 Dec 10.

Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California, USA.

Background: Clinicians and researchers commonly use global cognitive assessments to screen for impairment. Currently there are no published studies directly comparing the sensitivity and specificity of the Montreal Cognitive Assessment and Mattis Dementia Rating Scale-2 in PD. The objective of this study was to identify the relative sensitivity and specificity of the Montreal Cognitive Assessment and Mattis Dementia Rating Scale-2 in PD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.27575DOI Listing
February 2019

Clinical heterogeneity of frontotemporal dementia and Parkinsonism linked to chromosome 17 caused by MAPT N279K mutation in relation to tau positron emission tomography features.

Mov Disord 2019 Feb 17. Epub 2019 Feb 17.

Department of Neurology, Juntendo University School of Medicine, Tokyo, Japan.

Background: While mechanistic links between tau abnormalities and neurodegeneration have been proven in frontotemporal dementia and parkinsonism linked to chromosome 17 caused by MAPT mutations, variability of the tau pathogenesis and its relation to clinical progressions in the same MAPT mutation carriers are yet to be clarified.

Objectives: The present study aimed to analyze clinical profiles, tau accumulations, and their correlations in 3 kindreds with frontotemporal dementia and parkinsonism linked to chromosome 17 attributed to the MAPT N279K mutation.

Methods: Four patients with N279K mutant frontotemporal dementia and parkinsonism linked to chromosome 17/MAPT underwent [ C]PBB3-PET to estimate regional tau loads. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.27623DOI Listing
February 2019

Polysomnographic data in Dementia with Lewy Bodies: correlation with clinical symptoms and comparison with other α-synucleinopathies.

Sleep Med 2018 Dec 18;55:62-68. Epub 2018 Dec 18.

Department of Neurology, Hospital de Egas Moniz, Centro Hospitalar de Lisboa Ocidental, Lisboa, Portugal; CEDOC, Chronic Diseases Research Center, NOVA Medical School, USA.

Introduction: Sleep dysfunction is frequent in Dementia with Lewy Bodies (DLB), but polysomnographic (PSG) data is scarce. Our objectives were to: (1) compare PSG data between DLB patients and age normative values (NV), Parkinson's Disease (PD) and idiopathic REM sleep behavior disorder (iRBD) patients; (2) evaluate the relation between of OSA, Fluctuations and Hypersomnolence and PSG data.

Methods: We selected all consecutive patients with DLB, PD and iRBD that underwent video-PSG during a two year period. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.sleep.2018.12.006DOI Listing
December 2018
1 Read

Continuing pharmacy education practices in geriatric care among pharmacists in the Upper Midwest.

J Am Pharm Assoc (2003) 2019 Feb 13. Epub 2019 Feb 13.

Objectives: To summarize select continuing pharmacy education (CPE) topics and hours related to geriatric care completed by community, hospital/clinic, and long-term care (LTC)/consultant pharmacists in the previous 12 months, whether pharmacy workplace influenced topic selection or completion, and to describe CPE sources used by community versus hospital/clinic pharmacists.

Design: Cross-sectional survey (2017).

Setting And Participants: Licensed pharmacists in North Dakota, South Dakota, Minnesota, Iowa, and Nebraska with primary practice settings in community pharmacies, hospitals, or clinics or those practicing as consultant pharmacists. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.japh.2018.12.020DOI Listing
February 2019
1 Read

Abnormal α-synuclein deposits in skin nerves: intra- and inter-laboratory reproducibility.

Eur J Neurol 2019 Feb 15. Epub 2019 Feb 15.

Philipps University, Marburg, Germany.

Background: Visualization of phosphorylated α-synuclein at serine 129 (p-syn) in skin nerves is a promising test for the in vivo diagnosis of synucleinopathies. Here we aimed to establish the intra- and inter-laboratory reproducibility of quantification of intraneural p-syn immunoreactivity in two laboratories with a major expertise (Würzburg and Bologna).

Methods: We enrolled 43 patients affected by Parkinson's disease (PD: 21 patients), Dementia with Lewy Body (DLB: 1), REM sleep behavior disorder (RBD: 11), Multiple System Atrophy (MSA-P: 4) and small fiber neuropathy (SFN: 6). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ene.13939DOI Listing
February 2019
1 Read

Neurologic Conditions: Parkinson Disease.

FP Essent 2019 Feb;477:16-21

University of South Alabama College of Medicine Department of Family Medicine, 1601 Center Street, 2N Mobile, AL 36604.

Parkinson disease (PD) is a complex neurologic disorder that involves motor and nonmotor brain functions. PD is the second most common neurodegenerative disease after Alzheimer disease. Motor symptoms include resting tremor, cogwheel rigidity, extreme slowness of movement, shuffling gait, and impaired balance. Read More

View Article

Download full-text PDF

Source
February 2019
1 Read

COWAT Performance of Persons With Alzheimer's Dementia, Vascular Dementia, and Parkinson's Disease Dementia According to Stage of Cognitive Impairment.

PM R 2019 Feb 12. Epub 2019 Feb 12.

Department of Physical Medicine and Rehabilitation, Ilsan Paik Hospital, Inje University, Goyang, South Korea.

Background: The Controlled Oral Word Association Test (COWAT) evaluates frontal lobe and executive function. Therefore, it can be helpful in differentiating cognitive deficits. However, there are no studies comparing the COWAT performance according to the type and stage of cognitive impairment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pmrj.12125DOI Listing
February 2019
1 Read

MIBG Myocardial Scintigraphy Identifies Premotor PD/DLB During a Negative DAT Scan Period: Second Report.

Mov Disord Clin Pract 2019 Jan 9;6(1):46-50. Epub 2018 Nov 9.

Gastroenterology, Internal Medicine, Sakura Medical Center Toho University Sakura Japan.

Objectives: Neuroimaging markers for Parkinson's disease (PD)/dementia with Lewy bodies (DLB) include dopamine transporter (DAT) scanning and metaiodobenzylguanidine (MIBG) myocardial scintigraphy. It is unknown which marker is useful to identify the premotor phase PD/DLB. We reported four patients who, during a negative DAT scan period, had a positive MIBG result that suggested premotor PD/DLB. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mdc3.12697DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6335543PMC
January 2019
1 Read

Neural correlates of distinct cognitive phenotypes in early Parkinson's disease.

J Neurol Sci 2019 Feb 7;399:22-29. Epub 2019 Feb 7.

University of California San Diego, Department of Neurosciences, La Jolla, CA, USA.

Objective: Cognitive decline is common in Parkinson's disease (PD), but changes can occur in a variety of cognitive domains. The lack of a single cognitive phenotype complicates diagnosis and tracking. In an earlier study we used a data-driven approach to identify distinct cognitive phenotypes of early PD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jns.2019.02.013DOI Listing
February 2019
2 Reads

Toward the discovery and development of effective modulators of α-synuclein amyloid aggregation.

Eur J Med Chem 2019 Jan 28;167:10-36. Epub 2019 Jan 28.

Dipartimento di Scienze Chimiche, Università degli Studi di Catania, viale A. Doria 6, 95125, Catania, Italy. Electronic address:

A host of human diseases, including Parkinson's disease and Dementia with Lewy bodies, are suspected to be directly linked to protein aggregation. Amyloid protein aggregates and oligomeric intermediates of α-synuclein are observed in synucleinopathies and considered to be mediators of cellular toxicity. Hence, α-synuclein has seen as one of the leading and most compelling targets and is receiving a great deal of attention from researchers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejmech.2019.01.045DOI Listing
January 2019
1 Read

Gastrointestinal function in dementia with Lewy bodies: a comparison with Parkinson disease.

Clin Auton Res 2019 Feb 11. Epub 2019 Feb 11.

Gastroenterology, Internal Medicine, Sakura Medical Center, Toho University, Sakura, Japan.

Purpose: To investigate gastrointestinal function in dementia with Lewy bodies and Parkinson disease.

Methods: We examined gastric emptying and colonic transit time in 19 dementia with Lewy bodies and 46 Parkinson disease patients.

Results: Gastric emptying was longer in dementia with Lewy bodies than in Parkinson disease (p = 0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10286-019-00597-wDOI Listing
February 2019
1 Read

Tactile hallucinations in dementia with Lewy bodies.

Authors:
Katsuyuki Ukai

Psychogeriatrics 2019 Feb 7. Epub 2019 Feb 7.

Department of Psychogeriatrics, Kamiiida Daiichi General Hospital, Nagoya, Japan.

Background: Visual hallucinations (VH) are one of the most common psychological symptoms of dementia with Lewy bodies (DLB). It is generally considered that the VH that occur in DLB usually disappear when patients try to touch imaginary objects. However, DLB patients also sometimes experience tactile hallucinations (TH). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/psyg.12407DOI Listing
February 2019
1 Read

Management of delirium in Parkinson's disease.

J Neural Transm (Vienna) 2019 Feb 6. Epub 2019 Feb 6.

Department of Neurology, Charité-Universitätsmedizin Berlin, Hindenburgdamm 30, 12200, Berlin, Germany.

Delirium is an acute and fluctuating disturbance of attention and awareness. Pre-existing cognitive disturbances or dementia are the most significant risk factors for developing delirium and precipitating factors such as drug treatment, infections, trauma, or surgery may trigger delirium. Patients with Parkinson's disease (PD) are at an increased risk for delirium which may be underdiagnosed due to phenomenological overlap between delirium and chronic neuropsychiatric features of PD or side effects of dopaminergic medication. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00702-019-01980-7DOI Listing
February 2019
7 Reads

Role of epoxy-fatty acids and epoxide hydrolases in the pathology of neuro-inflammation.

Biochimie 2019 Feb 1. Epub 2019 Feb 1.

Department of Entomology and Nematology, UCD Comprehensive Cancer Center, University of California Davis, One Shields Avenue, Davis, CA, 95616, USA. Electronic address:

Neuroinflammation is a physiologic response aimed at protecting the central nervous system during injury. However, unresolved and chronic neuroinflammation can lead to long term damage and eventually neurologic disease including Parkinson's disease, Alzheimer's disease and dementia. Recently, enhancing the concentration of epoxyeicosatrienoic acids (EETs) through blocking their hydrolytic degradation by soluble epoxide hydrolase (sEH) has been applied towards reducing the long-term damage associated with central neurologic insults. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.biochi.2019.01.020DOI Listing
February 2019
1 Read

Insights into GBA Parkinson's disease pathology and therapy with induced pluripotent stem cell model systems.

Neurobiol Dis 2019 Jan 31. Epub 2019 Jan 31.

German Center for Neurodegenerative Diseases (DZNE), 72076 Tübingen, Germany; Center of Neurology, Hertie Institute for Clinical Brain Research, University of Tübingen, Germany. Electronic address:

While the link between GBA and Parkinson's disease (PD) was initially unexpected, it is now well established that GBA mutations are the most frequent genetic risk for PD. GBA has also been linked to sporadic PD, dementia with Lewy bodies, and ageing. Thus, GBA represents a promising target to counteract brain disease and the age-related decline of lysosomal function. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.nbd.2019.01.023DOI Listing
January 2019
2 Reads

Lewy Body Dementias.

Continuum (Minneap Minn) 2019 Feb;25(1):128-146

Purpose Of Review: This article describes current diagnostic criteria relating to the diagnosis of Lewy body dementia, highlights diagnostic controversies, and reviews treatment approaches.

Recent Findings: Clinical diagnostic criteria for both Parkinson disease and dementia with Lewy bodies have been recently updated. These criteria result in overlap between individuals diagnosed with Parkinson disease and those with dementia with Lewy bodies. Read More

View Article

Download full-text PDF

Source
http://Insights.ovid.com/crossref?an=00132979-201902000-0000
Publisher Site
http://dx.doi.org/10.1212/CON.0000000000000685DOI Listing
February 2019
4 Reads

The Alzheimer's Disease Clinical Spectrum: Diagnosis and Management.

Authors:
Alireza Atri

Med Clin North Am 2019 Mar;103(2):263-293

Banner Sun Health Research Institute, Banner Health, 10515 W Santa Fe Drive, Sun City, AZ 85351, USA; Department of Neurology, Brigham and Women's Hospital, 60 Fenwood Road, Boston, MA 02115, USA; Harvard Medical School, 25 Shattuck Street, Boston, MA 02115, USA. Electronic address:

Alzheimer's disease (AD) care requires timely diagnosis and multidisciplinary management. Evaluation involves structured patient and caregiver history and symptom-function reviews, examination, and testing (laboratory and neuroimaging) to delineate impairment level, determine the cognitive-behavioral syndrome, and diagnose cause. Clinical biomarkers are available to aid high confidence in etiologic diagnosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.mcna.2018.10.009DOI Listing
March 2019
9 Reads

Early perfusion and dopamine transporter imaging using F-FP-CIT PET/CT in patients with parkinsonism.

Am J Nucl Med Mol Imaging 2018 20;8(6):360-372. Epub 2018 Dec 20.

Department of Nuclear Medicine, Kyungpook National University Hospital Daegu, Republic of Korea.

Combined use of F-N-(3-fluoropropyl)-2β-carboxymethoxy-3β-(4-iodophenyl)nortropane (FP-CIT) for dopamine transporter imaging and F-fludeoxyglucose (FDG) for glucose metabolism shows good diagnostic performance for differential diagnosis of Parkinson disease (PD) and Parkinson plus syndrome (multiple system atrophy, progressive supranuclear palsy, corticobasal degeneration, and dementia with Lewy bodies). A recent study showed that F-FP-CIT positron emission tomography (PET) with early perfusion imaging is useful for the differential diagnosis of PD and Parkinson plus syndrome with lower radiation exposure, time, and cost. In this review, we summarize the advantages of using F-FP-CIT PET for perfusion and dopamine transporter imaging, as well as clinical features useful for the differential diagnosis of PD and Parkinson plus syndrome. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6334208PMC
December 2018
2 Reads

Episodic recognition memory and the hippocampus in Parkinson's disease: A review.

Cortex 2018 Dec 4;113:191-209. Epub 2018 Dec 4.

Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA; Department of Neurosurgery, Stanford University School of Medicine, Stanford, CA, USA. Electronic address:

Parkinson's disease is a progressive neurodegenerative disorder of aging. The hallmark pathophysiology includes the development of neuronal Lewy bodies in the substantia nigra of the midbrain with subsequent loss of dopaminergic neurons. These neuronal losses lead to the characteristic motor symptoms of bradykinesia, rigidity, and rest tremor. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cortex.2018.11.021DOI Listing
December 2018
5 Reads

Risk of Parkinson's disease dementia related to level I MDS PD-MCI.

Mov Disord 2019 Jan 17. Epub 2019 Jan 17.

Department of Medical Psychology, Academic Medical Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.

Background: The International Parkinson and Movement Disorders Society criteria for mild cognitive impairment in PD need validation. The objectives of this present study were to evaluate prognostic validity of level I (abbreviated) International Parkinson and Movement Disorders Society mild cognitive impairment in PD criteria for development of PD dementia and compared them with level II (comprehensive) criteria.

Methods: We analyzed data from 8 international studies (1045 patients) from our consortium that included baseline data on demographics, motor signs, depression, detailed neuropsychological testing, and longitudinal follow-up for conversion to Parkinson's disease dementia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.27617DOI Listing
January 2019
9 Reads

Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review.

Mov Disord 2019 Feb 17;34(2):180-198. Epub 2019 Jan 17.

CHDI Management/CHDI Foundation, Princeton, NJ, USA.

Objective: To update evidence-based medicine recommendations for treating nonmotor symptoms in Parkinson's disease (PD).

Background: The International Parkinson and Movement Disorder Society Evidence-Based Medicine Committee's recommendations for treatments of PD were first published in 2002, updated in 2011, and now updated again through December 31, 2016.

Methods: Level I studies testing pharmacological, surgical, or nonpharmacological interventions for the treatment of nonmotor symptoms in PD were reviewed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.27602DOI Listing
February 2019
2 Reads

Cell Responses to Extracellular α-Synuclein.

Molecules 2019 01 15;24(2). Epub 2019 Jan 15.

Department of Neurology, University of Kansas Medical Center, Kansas City, KS 66160, USA.

Synucleins are small naturally unfolded proteins involved in neurodegenerative diseases and cancer. The family contains three members: α-, β-, and -synuclein. α-Synuclein is the most thoroughly investigated because of its close association with Parkinson's disease (PD), dementia with Lewy bodies and multiple system atrophy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/molecules24020305DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6359176PMC
January 2019
1 Read

Role of Ketogenic Diets in Neurodegenerative Diseases (Alzheimer's Disease and Parkinson's Disease).

Nutrients 2019 Jan 15;11(1). Epub 2019 Jan 15.

Department of Dietetics, Faculty of Human Nutrition and Consumer Sciences, Warsaw University of Life Sciences (WULS-SGGW), 159c Nowoursynowska Str., 02-776 Warsaw, Poland.

The goal of this review was to assess the effectiveness of ketogenic diets on the therapy of neurodegenerative diseases. The ketogenic diet is a low-carbohydrate and fat-rich diet. Its implementation has a fasting-like effect, which brings the body into a state of ketosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/nu11010169DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6356942PMC
January 2019
3 Reads

The toxin MPTP generates similar cognitive and locomotor deficits in hTau and Tau Knock-Out mice.

Brain Res 2019 Jan 11. Epub 2019 Jan 11.

Université Laval, Faculté de Médecine, Département de Psychiatrie et Neurosciences, Québec, QC, Canada; Centre de recherche du Centre Hospitalier de l'Université Laval de Québec, Axe Neurosciences, Québec, QC, Canada. Electronic address:

Parkinson's disease (PD) is characterized by motor deficits, although cognitive disturbances are frequent and have been noted early in the disease. The main pathological characteristics of PD are the loss of dopaminergic neurons and the presence of aggregated α-synuclein in Lewy bodies of surviving cells. Studies have also documented the presence of other proteins within Lewy bodies, particularly tau, a microtubule-associated protein implicated in a wide range of neurodegenerative diseases, including Alzheimer's disease (AD). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.brainres.2019.01.016DOI Listing
January 2019
7 Reads

Prognosis and Neuropathologic Correlation of Clinical Subtypes of Parkinson Disease.

JAMA Neurol 2019 Jan 14. Epub 2019 Jan 14.

Reta Lila Weston Institute of Neurological Studies, University College London Queen Square Institute of Neurology, London, England.

Importance: Clinical subtyping of Parkinson disease at diagnosis is useful in estimating disease course and survival. Severity and rate of progression of neuropathologies are important determinants of clinical Parkinson subtypes.

Objective: To provide longitudinal clinical disease-course data and neuropathologic correlation for newly proposed Parkinson disease subtypes. Read More

View Article

Download full-text PDF

Source
http://archneur.jamanetwork.com/article.aspx?doi=10.1001/jam
Publisher Site
http://dx.doi.org/10.1001/jamaneurol.2018.4377DOI Listing
January 2019
21 Reads

Multimodal dopaminergic and free-water imaging in Parkinson's disease.

Parkinsonism Relat Disord 2019 Jan 6. Epub 2019 Jan 6.

Department of Applied Physiology and Kinesiology, University of Florida, Gainesville, FL,USA; Department of Neurology, University of Florida, Gainesville, FL,USA; Department of Biomedical Engineering, University of Florida, Gainesville, FL, USA. Electronic address:

Introduction: When using free-water diffusion imaging or positron emission tomography (PET), it is established that substania nigra microstructure and presynaptic dopamine activity are impaired in early PD. It is not well understood if these two forms of degeneration are redundant, or if they each provide a unique contribution to the clinical motor and cognitive symptoms.

Methods: A total of 129 PD and 75 control individuals underwent motor and cognitive evaluations, and in vivo [11C]dihydrotetrabenazine (DTBZ) monoaminergic brain PET imaging and diffusion imaging. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.parkreldis.2019.01.007DOI Listing
January 2019
2 Reads

Molecular Imaging of Dementia With Lewy Bodies.

Int Rev Neurobiol 2019 28;144:59-93. Epub 2018 Nov 28.

Neurodegeneration Imaging Group, Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology and Neuroscience (IoPPN), King's College London, London, United Kingdom. Electronic address:

Dementia with Lewy bodies (DLB) is the second most common cause of neurodegenerative dementia. The core clinical features of DLB include fluctuating cognition, visual hallucinations, rapid eye movement sleep behavior disorder, and parkinsonism. Molecular imaging is a powerful tool to assess the brain function in vivo. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/bs.irn.2018.10.007DOI Listing
November 2018
2 Reads

Neural Correlates of Cognitive Impairment in Parkinson's Disease: A Review of Structural MRI Findings.

Int Rev Neurobiol 2019 16;144:1-28. Epub 2018 Oct 16.

Brain and Mind Centre, University of Sydney, Camperdown, NSW, Australia. Electronic address:

Cognitive impairment is one of the most salient non-motor symptoms of Parkinson's disease (PD). Cognitive decline poses a significant burden on the patient as well as the caregiver and a better understanding of the underlying pathological processes will aid in directing disease-specific treatment. In recent years, significant progress in the understanding of the underlying mechanisms of cognition in PD has been made using neuroimaging modalities. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/bs.irn.2018.09.009DOI Listing
October 2018
2 Reads

Identifying the neural correlates of doorway freezing in Parkinson's disease.

Hum Brain Mapp 2019 Jan 13. Epub 2019 Jan 13.

Parkinson's Disease Research Clinic, Brain and Mind Centre, The University of Sydney, Camperdown, New South Wales, Australia.

Freezing of gait (FOG) in Parkinson's disease (PD) is frequently triggered upon passing through narrow spaces such as doorways. However, despite being common the neural mechanisms underlying this phenomenon are poorly understood. In our study, 19 patients who routinely experience FOG performed a previously validated virtual reality (VR) gait paradigm where they used foot-pedals to navigate a series of doorways. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hbm.24506DOI Listing
January 2019
5 Reads

Data-Driven Based Approach to Aid Parkinson's Disease Diagnosis.

Sensors (Basel) 2019 Jan 10;19(2). Epub 2019 Jan 10.

Laboratory of Images, Signals and Intelligent Systems (LISSI), University of Paris-Est Créteil (UPEC), 122 rue Paul Armangot, 94400 Vitry-Sur-Seine, France.

This article presents a machine learning methodology for diagnosing Parkinson's disease (PD) based on the use of vertical Ground Reaction Forces (vGRFs) data collected from the gait cycle. A classification engine assigns subjects to healthy or Parkinsonian classes. The diagnosis process involves four steps: data pre-processing, feature extraction and selection, data classification and performance evaluation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/s19020242DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6359125PMC
January 2019
6 Reads

Cognitive Stimulation for Individuals with Parkinson's Disease Dementia Living in Long-Term Care: Preliminary Data from a Randomized Crossover Pilot Study.

Parkinsons Dis 2018 2;2018:8104673. Epub 2018 Dec 2.

Medical Psychology | Neuropsychology and Gender Studies & Center for Neuropsychological Diagnostics and Intervention (CeNDI), University Hospital Cologne, Kerpenerstraβe 62, 50937 Cologne, Germany.

Background: While the efficacy of cognitive stimulation (CS) has been demonstrated in patients with dementia, no study has included patients with Parkinson's disease dementia (PDD).

Objective: For the first time, this randomized crossover pilot study examined the feasibility and potential effects of CS in PDD.

Methods: All residents of a PDD-specific long-term care unit in the Netherlands that were eligible for the study (=12) were randomly allocated to group A (=6) receiving CS (eight weeks, twice weekly for 60 minutes) or group B (=6) receiving usual care (control group, CG). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2018/8104673DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6304852PMC
December 2018
12 Reads

Same day cerebral perfusion and dopamine transporter imaging for differential diagnosis of cerebral impairment.

Authors:
Thomas J Biggans

Med Eng Phys 2019 Feb 8;64:56-64. Epub 2019 Jan 8.

Nuclear Medicine, Ninewells Hospital, Dundee, DD1 9SY, United Kingdom. Electronic address:

When cognitive impairment is first evident it can be difficult to distinguish between different conditions such as idiopathic Parkinson's disease and Lewy body dementia. Imaging both cerebral perfusion and dopamine transporter function has been shown to provide accurate differentiation between the most common conditions. At present cerebral perfusion and dopamine transporter imaging is conducted on separate days. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S13504533193000
Publisher Site
http://dx.doi.org/10.1016/j.medengphy.2018.12.016DOI Listing
February 2019
6 Reads

Simultaneous Stimulation of the Globus Pallidus Interna and the Nucleus Basalis of Meynert in the Parkinson-Dementia Syndrome.

Dement Geriatr Cogn Disord 2019 Jan 10;47(1-2):19-28. Epub 2019 Jan 10.

Department of Neurosurgery, Hospital Clínico San Carlos, Health Research Institute of the Hospital Clínico San Carlos, Madrid, Spain.

Background/aim: The prevalence of cognitive symptoms in recently diagnosed Parkinson's disease (PD) patients may be as high as 60%. We report a novel deep brain stimulation (DBS) strategy targeting both motor and cognitive symptoms.

Methods: A PD patient diagnosed with mild cognitive impairment underwent DBS surgery targeting the globus pallidus interna (GPi; to treat motor symptoms) and the nucleus basalis of Meynert (NBM; to treat cognitive symptoms) using a single electrode per hemisphere. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000493094DOI Listing
January 2019
3 Reads
3.547 Impact Factor

A smartphone application for automated decision support in cognitive task based evaluation of central nervous system motor disorders.

IEEE J Biomed Health Inform 2019 Jan 9. Epub 2019 Jan 9.

Background And Objective: New technology enables constant boost to the powers of mobile devices, which in the previous years have transformed from simple mobile phones to smart phones. Computational powers of these electronics enable actions that previously were possible only for computers. By the use of special applications we may benefit from sensors and multimedia capabilities of operating systems. Read More

View Article

Download full-text PDF

Source
https://ieeexplore.ieee.org/document/8606105/
Publisher Site
http://dx.doi.org/10.1109/JBHI.2019.2891729DOI Listing
January 2019
7 Reads

Distinct Incidence of Takotsubo Syndrome Between Amyotrophic Lateral Sclerosis and Synucleinopathies: A Cohort Study.

Front Neurol 2018 13;9:1099. Epub 2018 Dec 13.

Department of Clinical Neuroscience, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan.

Takotsubo syndrome (TTS) is an acute cardiac syndrome characterized by regional left ventricular dysfunction with a peculiar circumferential pattern, which typically results in apical ballooning. Evidence indicates a pivotal role of catecholamines in TTS, and researchers have discussed multiple hypotheses on the etiology, including multivessel coronary spasm, myocardial stunning, excessive transient ventricular afterload, and cardiac sympathetic overactivity with local noradrenaline spillover. Although central nervous system disorders, such as stroke and epilepsy, are known to trigger TTS, the incidence and clinical features of TTS in neurodegenerative disorders are poorly understood. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fneur.2018.01099DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6300466PMC
December 2018
2 Reads

F-AV-1451 uptake differs between dementia with lewy bodies and posterior cortical atrophy.

Mov Disord 2019 Jan 7. Epub 2019 Jan 7.

Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA.

Background: Posterior cortical atrophy and dementia with Lewy bodies are 2 distinct clinical syndromes, yet they can overlap in symptoms and occipital hypometabolism. Patients with dementia with Lewy bodies often have overlapping Alzheimer's disease pathology. Similarly, Lewy bodies can be found in patients with posterior cortical atrophy. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/mds.27603
Publisher Site
http://dx.doi.org/10.1002/mds.27603DOI Listing
January 2019
6 Reads

Assessment of Use of Combined Dextromethorphan and Quinidine in Patients With Dementia or Parkinson Disease After US Food and Drug Administration Approval for Pseudobulbar Affect.

JAMA Intern Med 2019 Feb;179(2):224-230

Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

Importance: In 2010, the US Food and Drug Administration (FDA) approved a combination of dextromethorphan hydrobromide and quinidine sulfate for the treatment of pseudobulbar affect after studies in patients with amyotrophic lateral sclerosis (ALS) or multiple sclerosis (MS). This medication, however, may be commonly prescribed in patients with dementia and/or Parkinson disease (PD).

Objective: To investigate the prescribing patterns of dextromethorphan-quinidine, including trends in associated costs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamainternmed.2018.6112DOI Listing
February 2019
1 Read

Neuroimaging findings and clinical trajectories of Lewy body disease in patients with MCI.

Neurobiol Aging 2018 Dec 13;76:9-17. Epub 2018 Dec 13.

Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI), University of Genoa, Genoa, Italy; Clinica Neurologica, IRCCS Ospedale Policlinico, San Martino, Genoa, Italy. Electronic address:

Elderly patients with mild cognitive impairment (MCI) may develop a Lewy body disease; their neuroimaging features at presentation are largely unknown. We present an intriguing group of 13 patients with MCI preceding (2.9 ± 1. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neurobiolaging.2018.12.001DOI Listing
December 2018
3 Reads

Glucocerebrosidase mutations and synucleinopathies: Toward a model of precision medicine.

Mov Disord 2019 Jan 27;34(1):9-21. Epub 2018 Dec 27.

Programa de Neurociencias, Fundación para la Investigación Médica Aplicada (FIMA), Universidad de Navarra, Pamplona, Spain.

Glucocerebrosidase is a lysosomal enzyme. The characterization of a direct link between mutations in the gene coding for glucocerebrosidase (GBA1) with the development of Parkinson's disease and dementia with Lewy bodies has heightened interest in this enzyme. Although the mechanisms through which glucocerebrosidase regulates the homeostasis of α-synuclein remains poorly understood, the identification of reduced glucocerebrosidase activity in the brains of patients with PD and dementia with Lewy bodies has paved the way for the development of novel therapeutic strategies directed at enhancing glucocerebrosidase activity and reducing α-synuclein burden, thereby slowing down or even preventing neuronal death. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/mds.27583
Publisher Site
http://dx.doi.org/10.1002/mds.27583DOI Listing
January 2019
12 Reads

Risk factors for possible REM sleep behavior disorder: A CLSA population-based cohort study.

Neurology 2018 Dec 26. Epub 2018 Dec 26.

From the Integrated Program in Neuroscience (C.Y.), Department of Neurology and Neurosurgery (S.-M.F., R.B.P.), Department of Epidemiology and Biostatistics and Occupational Health (C.W.), and Department of Medicine (C.W., A.P.), McGill University; Centre de Recherche du Centre hospitalier de l'Université de Montréal (M.R.K.); and Research Institute of the McGill University Health Centre (C.W., A.P.), Montreal, Quebec, Canada.

Objective: To assess sociodemographic, socioeconomic, and clinical correlates of idiopathic REM sleep behavior disorder (RBD) in a 30,097-person national cohort.

Methods: Participants 45 to 85 years of age in Canada were collected as part of the Canadian Longitudinal Study on Aging. Possible RBD (pRBD) was screened with the REM Sleep Behavior Disorder Single-Question Screen, a questionnaire with 94% specificity and 87% sensitivity. Read More

View Article

Download full-text PDF

Source
http://www.neurology.org/lookup/doi/10.1212/WNL.000000000000
Publisher Site
http://dx.doi.org/10.1212/WNL.0000000000006849DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6369902PMC
December 2018
19 Reads

Resting-state fMRI in Parkinson's disease patients with cognitive impairment: A meta-analysis.

Parkinsonism Relat Disord 2018 Dec 17. Epub 2018 Dec 17.

Department of Neurology, Maastricht University Medical Centre, P.O. Box 5800, 6202, AZ, Maastricht, the Netherlands. Electronic address:

Background: Cognitive impairment is a common non-motor symptom in Parkinson's disease. So far, the underlying pathophysiology remains unclear. Several alterations in functional network connectivity have been described in Parkinson's disease patients with cognitive impairment which are probably the result of the heterogenous pathophysiology underlying this cognitive decline, including dopaminergic and cholinergic deficits. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.parkreldis.2018.12.016DOI Listing
December 2018
2 Reads

Olfactory Dysfunction and Its Relationship with Clinical Symptoms of Alzheimer Disease.

Aging Dis 2018 Dec 4;9(6):1084-1095. Epub 2018 Dec 4.

1Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100050, China.

Our study aimed to analyse the olfactory dysfunction (OD) evaluations between self-report, the Hyposmia Rating Scale (HRS) and the Sniffin' Sticks test, and the relationship between OD and clinical features of AD. Sixty patients with AD dementia, 37 patients with mild cognitive impairment (MCI) due to AD and 30 healthy controls were consecutively recruited. Olfactory function was evaluated by self-report, HRS and Sniffin' Sticks test. Read More

View Article

Download full-text PDF

Source
http://www.aginganddisease.org/EN/10.14336/AD.2018.0819
Publisher Site
http://dx.doi.org/10.14336/AD.2018.0819DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6284764PMC
December 2018
6 Reads

Carriers of both GBA and LRRK2 mutations, compared to carriers of either, in Parkinson's disease: Risk estimates and genotype-phenotype correlations.

Parkinsonism Relat Disord 2018 Dec 13. Epub 2018 Dec 13.

The Movement Disorders Institute, Department of Neurology and Sagol Neuroscience Center, Sheba Medical Center, Tel Hashomer, Israel; Sackler Faculty of Medicine, Tel-Aviv University, Israel.

Introduction: The clinical characteristics of Parkinson's disease (PD) associated with both the LRRK2 p.G2019S mutation and a GBA variant (LRRK2-GBA-PD) have not yet been determined.

Methods: In this retrospective observational study of Ashkenazi-Jewish (AJ) PD patients, we describe the clinical course and characteristics of LRRK2-GBA-PD and estimate the risk to develop PD for the double mutation carriers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.parkreldis.2018.12.014DOI Listing
December 2018
1 Read
3.972 Impact Factor

Clinical relevance of amnestic versus non-amnestic mild cognitive impairment subtyping in Parkinson's disease.

Eur J Neurol 2018 Dec 18. Epub 2018 Dec 18.

Department of Neurology, Yonsei University College of Medicine, Seoul.

Background And Purpose: To clarify whether subtyping of amnestic and non-amnestic mild cognitive impairment (MCI) is clinically relevant in Parkinson's disease (PD) by analyzing patterns of neuroimaging and longitudinal cognitive changes.

Methods: We performed comparative analyses of cortical thickness, hippocampal volume, white matter integrity and resting-state functional connectivity between the patients with de-novo PD with amnestic MCI (PD-aMCI) (n = 50) and non-amnestic MCI (PD-naMCI) (n = 50) subtypes. Additionally, we assessed the longitudinal rate of cognitive decline in each cognitive domain over time and the rate of dementia conversion in patients with de-novo PD-aMCI (n = 125) and PD-naMCI (n = 61). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ene.13886DOI Listing
December 2018
2 Reads

Cognitive and Pathological Influences of Tau Pathology in Lewy Body Disorders.

Ann Neurol 2019 Feb 7;85(2):259-271. Epub 2019 Jan 7.

Department of Neurology, Perelman School of Medicine at the University of Pennsylvania.

Objective: To use digital histology in a large autopsy cohort of Lewy body disorder (LBD) patients with dementia to test the hypotheses that co-occurring Alzheimer disease (AD) pathology impacts the anatomic distribution of α-synuclein (SYN) pathology and that co-occurring neocortical tau pathology in LBDs associates with worse cognitive performance and occurs in a pattern differing from AD.

Methods: Fifty-five autopsy-confirmed LBD (Parkinson disease with dementia, n = 36; dementia with Lewy bodies, n = 19) patients and 25 AD patients were studied. LBD patients were categorized as having moderate/severe AD copathology (SYN + AD = 20) or little/no AD copathology (SYN-AD = 35). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ana.25392DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6375484PMC
February 2019
2 Reads

The Potential Use of Plant Natural Products and Plant Extracts with Antioxidant Properties for the Prevention/Treatment of Neurodegenerative Diseases: In Vitro, In Vivo and Clinical Trials.

Molecules 2018 Dec 11;23(12). Epub 2018 Dec 11.

School of Pharmacy and Life Sciences, Robert Gordon University, Aberdeen AB10 7GJ, UK.

Neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease and Huntington's disease, present a major health issue and financial burden for health care systems around the world. The impact of these diseases will further increase over the next decades due to increasing life expectancies. No cure is currently available for the treatment of these conditions; only drugs, which merely alleviate the symptoms. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/molecules23123283DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6321248PMC
December 2018
1 Read